Dinutuximab beta

Drug Profile

Dinutuximab beta

Alternative Names: APN 311; ch14.18/CHO; Dinutuximab beta Apeiron; ISQETTE

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Children's Cancer Research Institute
  • Developer Apeiron Biologics; Children's Cancer Research Institute; Nagoya University; SIOPEN
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action GD2 ganglioside inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Neuroblastoma

Most Recent Events

  • 10 May 2017 Registered for Neuroblastoma (Combination therapy, In adolescents, In children, In infants, Recurrent, Refractory metastatic disease, Second-line therapy or greater, In adults) in European Union (IV)
  • 10 May 2017 Registered for Neuroblastoma (Combination therapy, In adolescents, In children, In infants, Recurrent, Refractory metastatic disease, Second-line therapy or greater, In adults) in Liechtenstein, Iceland, Norway (IV)
  • 10 May 2017 Registered for Neuroblastoma (In adolescents, In children, In infants, Recurrent, Refractory metastatic disease, Second-line therapy or greater, In adults) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top